Treatment regimens for HER2+ BCa typically involve ErbB2-targeted therapies including trastuzumab in combination with chemotherapies such as the anthracycline doxorubicin and alkylating agent cyclophosphamide to enhance the anti-tumor effects of HER2-blockade, albeit increasing the cardiotoxic risk from 3-7% to 27% of patients7–9. This evidence concerns the gene ERBB2 and neoplasm.